 Home > Active Ingredient News > Blood System > NICE guidelines support isatuximab treatment for multiple myeloma (MM)

NICE guidelines support isatuximab treatment for multiple myeloma (MM)

 Last Update: 2020-12-16
 Source: Internet
 Author: User

Tags

rickets bone disease

gastrointestinal assessment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Patients with recurring multiple myeloma can now get Sarclisa on the NHS in England and Wales after cost regulator NICE published final guidelines for Sanofi Sarclisa( isatuximab).
NICE guidelines recommend sarclisa in a joint pomalidomide and dexamison treatment for relapsed and incurable multiple myeloma.
institute said there was no regular NHS funding at the time because of the limited clinical data and uncertainty about cost-effectiveness.
Childt Boysen, chief executive of NICE Health Technology Assessment Centre, said: "Our independent assessment committee has recognised that patients with multiple myeloma who are difficult to treat need more treatment options.
some of the data we have seen from our committee suggest that Sarclisa combined pomalidomide and dexamisson can slow the progression of the disease and extend the life of patients compared to current treatment options."
multiple myeloma is a malignant tumor (cancer) that causes abnormal growth of plasma cells that invade the bone marrow.
multiple myeloma is mostly asymptomatic at first, if the disease worsens, there will be bone pain, often infected, anemia symptoms.
。

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Atipamezole hydrochloride 104075-48-1 reduce sedation lower blood pressure

CAS No.: 104075-48-1

Pharm grade

$1/G EXW

Pharma Grade Fasudil hydrochloride CAS:105628-07-7 for High Purity

CAS No.: 105628-07-7

Pharmacy Grade;

$4.8-5.5/G FOB

Nutritional Supplement Chemicals Whey Protein CAS:91082-88-1/84082-51-9 for Food Grdade

CAS No.: 84082-51-9

Pharmacy Grade;

$40-50/KG FOB

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.